Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

Current pharmacotherapeutic options for myasthenia gravis.

Barnett C, Tabasinejad R, Bril V.

Expert Opin Pharmacother. 2019 Oct 31:1-9. doi: 10.1080/14656566.2019.1682548. [Epub ahead of print]

PMID:
31670984
2.

A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations.

Karelis G, Balasa R, De Bleecker JL, Stuchevskaya T, Villa A, Van Damme P, Lagrange E, Heckmann JM, Nicolle M, Vilciu C, Bril V, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubi S, Ayguasanosa J.

Eur Neurol. 2019 Oct 25:1-8. doi: 10.1159/000502818. [Epub ahead of print]

PMID:
31655810
3.

Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes.

Cardinez N, Lovblom LE, Orszag A, Bril V, Cherney DZ, Perkins BA.

J Diabetes Complications. 2019 Jun 20:107397. doi: 10.1016/j.jdiacomp.2019.06.002. [Epub ahead of print]

PMID:
31640908
4.

European Federation of Neurological Societies cutoff values significantly reduce creatine kinase sensitivity for diagnosing neuromuscular disorders.

Abraham A, Katzberg HD, Lovblom LE, Bril V.

Muscle Nerve. 2019 Sep 8. doi: 10.1002/mus.26701. [Epub ahead of print]

PMID:
31495916
5.

Muscle thickness measured by ultrasound is reduced in neuromuscular disorders and correlates with clinical and electrophysiological findings.

Abraham A, Drory VE, Fainmesser Y, Algom AA, Lovblom LE, Bril V.

Muscle Nerve. 2019 Sep 3. doi: 10.1002/mus.26693. [Epub ahead of print]

PMID:
31478199
6.

Evidence of small-fiber neuropathy in neurofibromatosis type 1.

Barnett C, Alon T, Abraham A, Kim RH, McCuaig JM, Kongkham P, Maurice C, Suppiah S, Zadeh G, Bril V.

Muscle Nerve. 2019 Aug 29. doi: 10.1002/mus.26687. [Epub ahead of print]

PMID:
31465118
7.

Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes.

Breiner A, Barnett Tapia C, Lovblom LE, Perkins BA, Katzberg HD, Bril V.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 10;6(5). pii: e586. doi: 10.1212/NXI.0000000000000586. Print 2019 Sep.

8.

Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity.

Katzberg HD, Bril V, Riaz S, Barnett C.

Can J Neurol Sci. 2019 Nov;46(6):735-741. doi: 10.1017/cjn.2019.286.

PMID:
31452475
9.

Chronic stress, depression and personality type in patients with myasthenia gravis.

Bogdan A, Barnett C, Ali A, AlQwaifly M, Abraham A, Mannan S, Ng E, Bril V.

Eur J Neurol. 2019 Aug 13. doi: 10.1111/ene.14057. [Epub ahead of print]

PMID:
31408565
10.

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.

Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group.

Eur J Neurol. 2019 Aug 10. doi: 10.1111/ene.14056. [Epub ahead of print]

PMID:
31400231
11.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep.

12.

Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.

Abraham A, Lovblom LE, Bril V.

Can J Neurol Sci. 2019 Nov;46(6):762-766. doi: 10.1017/cjn.2019.246.

PMID:
31322098
13.

Acute Intermittent Porphyria: A Report of 3 Cases with Neuropathy.

Alqwaifly M, Bril V, Dodig D.

Case Rep Neurol. 2019 Feb 8;11(1):32-36. doi: 10.1159/000496420. eCollection 2019 Jan-Apr.

14.

Diabetic neuropathy.

Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V.

Nat Rev Dis Primers. 2019 Jun 13;5(1):41. doi: 10.1038/s41572-019-0092-1. Review.

PMID:
31197153
15.

Estimating GFR by Serum Creatinine, Cystatin C, and β2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Scarr D, Bjornstad P, Lovblom LE, Lovshin JA, Boulet G, Lytvyn Y, Farooqi MA, Lai V, Orszag A, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Cherney DZI, Perkins BA.

Kidney Int Rep. 2019 Feb 21;4(6):786-796. doi: 10.1016/j.ekir.2019.02.010. eCollection 2019 Jun.

16.

Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report.

Bjornstad P, Lovshin JA, Lytvyn Y, Lovblom LE, Scarr D, Boulet G, Farooqi MA, Orszag A, Bai JW, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI.

J Diabetes Complications. 2019 Aug;33(8):547-549. doi: 10.1016/j.jdiacomp.2019.05.007. Epub 2019 May 17.

PMID:
31186164
17.

Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes.

Sekercioglu N, Lovblom LE, Bjornstad P, Lovshin JA, Lytvyn Y, Boulet G, Farooqi MA, Orszag A, Lai V, Tse J, Cham L, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI.

Ren Fail. 2019 Nov;41(1):427-433. doi: 10.1080/0886022X.2019.1614057.

18.

Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations.

Breiner A, Ebadi H, Bril V, Barnett C, Katzberg HD.

J Clin Neuromuscul Dis. 2019 Jun;20(4):165-172. doi: 10.1097/CND.0000000000000250.

PMID:
31135619
19.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
20.

Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.

Alhuzaim ON, Lewis EJH, Lovblom LE, Cardinez M, Scarr D, Boulet G, Weisman A, Lovshin JA, Lytvyn Y, Keenan HA, Brent MH, Paul N, Bril V, Cherney DZI, Perkins BA.

J Diabetes Complications. 2019 Nov;33(11):107324. doi: 10.1016/j.jdiacomp.2018.12.009. Epub 2018 Dec 22.

PMID:
31003922
21.

Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects.

Abraham A, Katzberg HD, Lovblom LE, Perkins BA, Bril V.

Can J Neurol Sci. 2019 May;46(3):337-341. doi: 10.1017/cjn.2019.9. Epub 2019 Mar 18.

PMID:
30880660
22.

Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.

Lytvyn Y, Bjornstad P, Lovshin JA, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI.

Am J Kidney Dis. 2019 Jun;73(6):786-796. doi: 10.1053/j.ajkd.2018.12.034. Epub 2019 Feb 22.

PMID:
30799029
23.

Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes.

Lytvyn Y, Bjornstad P, Lovshin JA, Singh SK, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI.

Diabetes Obes Metab. 2019 Jun;21(6):1388-1398. doi: 10.1111/dom.13665. Epub 2019 Mar 28.

PMID:
30761725
24.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.

25.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group.

J Peripher Nerv Syst. 2019 Mar;24(1):72-79. doi: 10.1111/jns.12303. Epub 2019 Mar 1.

26.

Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Lovshin JA, Lytvyn Y, Lovblom LE, Katz A, Boulet G, Bjornstad P, Lai V, Cham L, Tse J, Orszag A, Keenan HA, Paul N, Bril V, Wong DT, McReelis KD, Brent MH, Perkins BA, Cherney DZI.

Diabetes Care. 2019 Feb;42(2):273-280. doi: 10.2337/dc18-1809. Epub 2018 Dec 6.

PMID:
30523033
27.

Ultrasound-Assisted Lumbar Puncture in a Neuromuscular Clinic has a High Success Rate and Less Pain.

Abraham A, Breiner A, Katzberg HD, Lovblom LE, Bril V.

Can J Neurol Sci. 2019 Jan;46(1):79-82. doi: 10.1017/cjn.2018.351. Epub 2018 Nov 13.

PMID:
30419981
28.

EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis.

Barnett C, Bril V, Bayoumi AM.

Eur J Neurol. 2019 Mar;26(3):452-459. doi: 10.1111/ene.13836. Epub 2018 Nov 16.

PMID:
30315714
29.

The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.

Bjornstad P, Singh SK, Snell-Bergeon JK, Lovshin JA, Lytvyn Y, Lovblom LE, Rewers MJ, Boulet G, Lai V, Tse J, Cham L, Orszag A, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI.

Diabetes Obes Metab. 2019 Mar;21(3):575-583. doi: 10.1111/dom.13556. Epub 2018 Nov 11.

PMID:
30311395
30.

Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Lovshin JA, Bjornstad P, Lovblom LE, Bai JW, Lytvyn Y, Boulet G, Farooqi MA, Santiago S, Orszag A, Scarr D, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI.

Diabetes Care. 2018 Dec;41(12):2570-2578. doi: 10.2337/dc18-1236. Epub 2018 Oct 1.

PMID:
30275283
31.

The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome.

Jiwa N, Abraham A, Bril V, Katzberg HD, Lovblom LE, Barnett C, Breiner A.

Clin Neurophysiol. 2018 Nov;129(11):2239-2244. doi: 10.1016/j.clinph.2018.08.008. Epub 2018 Aug 31.

PMID:
30216907
32.

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia.

Kavanagh S, Bril V, Lipton JH.

Blood Res. 2018 Jun;53(2):172-174. doi: 10.5045/br.2018.53.2.172. Epub 2018 Jun 25. No abstract available.

33.

Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.

Cardinez N, Lovblom LE, Bai JW, Lewis E, Abraham A, Scarr D, Lovshin JA, Lytvyn Y, Boulet G, Farooqi MA, Orszag A, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Cherney DZ, Perkins BA.

J Diabetes Complications. 2018 Jul;32(7):660-664. doi: 10.1016/j.jdiacomp.2018.05.001. Epub 2018 May 5.

PMID:
29929836
34.

Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study.

Perkins BA, Lovblom LE, Bril V, Scarr D, Ostrovski I, Orszag A, Edwards K, Pritchard N, Russell A, Dehghani C, Pacaud D, Romanchuk K, Mah JK, Jeziorska M, Marshall A, Shtein RM, Pop-Busui R, Lentz SI, Boulton AJM, Tavakoli M, Efron N, Malik RA.

Diabetologia. 2018 Aug;61(8):1856-1861. doi: 10.1007/s00125-018-4653-8. Epub 2018 Jun 4.

35.

Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI.

Gwathmey KG, Sadjadi R, Horton WB, Conaway MR, Barnett-Tapia C, Bril V, Russell JW, Shaibani A, Mauermann ML, Hehir MK, Kolb N, Guptill J, Hobson-Webb L, Gable K, Raja S, Silvestri N, Wolfe GI, Smith AG, Malik R, Traub R, Joshi A, Elliott MP, Jones S, Burns TM.

Neurology. 2018 Jun 5;90(23):e2034-e2041. doi: 10.1212/WNL.0000000000005643. Epub 2018 May 4.

36.

Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.

Scarr D, Lovblom LE, Cardinez N, Orszag A, Farooqi MA, Boulet G, Weisman A, Lovshin JA, Ngo M, Paul N, Keenan HA, Brent MH, Cherney DZ, Bril V, Perkins BA.

PLoS One. 2018 Apr 30;13(4):e0196647. doi: 10.1371/journal.pone.0196647. eCollection 2018.

37.

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V; BEL115123 Study Group.

Neurology. 2018 Apr 17;90(16):e1425-e1434. doi: 10.1212/WNL.0000000000005323. Epub 2018 Mar 21.

38.

Neuropathy.

Diabetes Canada Clinical Practice Guidelines Expert Committee, Bril V, Breiner A, Perkins BA, Zochodne D.

Can J Diabetes. 2018 Apr;42 Suppl 1:S217-S221. doi: 10.1016/j.jcjd.2017.10.028. No abstract available.

PMID:
29650100
39.

Muscle biopsy technical safety and quality using a self-contained, vacuum-assisted biopsy technique.

Gallo A, Abraham A, Katzberg HD, Ilaalagan S, Bril V, Breiner A.

Neuromuscul Disord. 2018 May;28(5):450-453. doi: 10.1016/j.nmd.2018.02.006. Epub 2018 Feb 15.

PMID:
29631953
40.

Sex differences in neuropathic pain intensity in diabetes.

Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V.

J Neurol Sci. 2018 May 15;388:103-106. doi: 10.1016/j.jns.2018.03.008. Epub 2018 Mar 6.

PMID:
29627001
41.

Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Bjornstad P, Lovshin JA, Lytvyn Y, Boulet G, Lovblom LE, Alhuzaim ON, Farooqi MA, Lai V, Tse J, Cham L, Orszag A, Scarr D, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI.

Diabetes Care. 2018 Apr;41(4):831-839. doi: 10.2337/dc17-2475. Epub 2018 Feb 2.

42.

Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations.

Abraham A, Breiner A, Barnett C, Katzberg HD, Ngo M, Lovblom LE, Perkins BA, Bril V.

Can J Neurol Sci. 2018 May;45(3):346-349. doi: 10.1017/cjn.2017.298. Epub 2018 Feb 13.

PMID:
29433597
43.

Nerve function varies with hemoglobin A1c in controls and type 2 diabetes.

Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V.

J Diabetes Complications. 2018 Apr;32(4):424-428. doi: 10.1016/j.jdiacomp.2017.12.007. Epub 2017 Dec 21.

PMID:
29422233
44.

Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study.

Siddiqi ZA, Courtney K, Hanna K, Mondou E, Bril V.

Can J Neurol Sci. 2017 Nov;44(6):711-717. doi: 10.1017/cjn.2017.205.

PMID:
29391076
45.

Fatigue is a relevant outcome in patients with myasthenia gravis.

Tran C, Bril V, Katzberg HD, Barnett C.

Muscle Nerve. 2018 Aug;58(2):197-203. doi: 10.1002/mus.26069. Epub 2018 Feb 5.

PMID:
29342314
46.

Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes.

Lovshin JA, Boulet G, Lytvyn Y, Lovblom LE, Bjornstad P, Farooqi MA, Lai V, Cham L, Tse J, Orszag A, Scarr D, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZ.

JCI Insight. 2018 Jan 11;3(1). pii: 96968. doi: 10.1172/jci.insight.96968. eCollection 2018 Jan 11.

47.

High frequency of MGUS in DSP.

Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V.

Muscle Nerve. 2018 Jun;57(6):1018-1021. doi: 10.1002/mus.26054. Epub 2018 Feb 2.

PMID:
29314079
48.

Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies.

Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V.

Eur J Neurol. 2018 Mar;25(3):484-490. doi: 10.1111/ene.13533. Epub 2017 Dec 26.

PMID:
29194856
49.

Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes.

Abraham A, Barnett C, Lovblom LE, Perkins BA, Bril V, Katzberg HD.

Clin Neurophysiol. 2018 Jan;129(1):122-126. doi: 10.1016/j.clinph.2017.10.029. Epub 2017 Nov 11.

PMID:
29175104
50.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Erratum in: Lancet Neurol. 2018 Jan;17 (1):26. Erratum in: Lancet Neurol. 2018 Aug;17(8):661.

PMID:
29122523

Supplemental Content

Support Center